# Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

> **NCT02650817** · PHASE1 · COMPLETED · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** RAD1901

## Key facts

- **NCT ID:** NCT02650817
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2018-08-30
- **Final completion:** 2019-10-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650817, "Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02650817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*